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The methylation of arginine has been implicated in many cellular processes, such as regulation of transcription, mRNA splicing, RNA
metabolism and transport. The enzymes responsible for this modification are the protein arginine methyltransferases. The most
abundant methyltransferase in human cells is protein arginine methyltransferase 1. Methylation processes appear to interfere in the
emergence of several diseases, including cancer. During our study, we examined the expression pattern of protein arginine
methyltransferase 1 gene in colon cancer patients. The emerging results showed that the expression of one of the gene variants is
associated with statistical significant probability to clinical and histological parameters, such as nodal status and stage. This is a first
attempt to acquire an insight on the possible relation of the expression pattern of protein arginine methyltransferase 1 and colon
cancer progression.
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Colon cancer is one of the most dominant types of cancer in
Western industrialised countries. There are many hereditary
syndromes that significantly increase the possibility of colon
cancer occurrence, such as familial adenomatous polyposis coli
and hereditary non-polyposis coli. Almost 40% of colorectal
cancers are diagnosed with localised disease, which have
approximately a 90% 5-year survival rate. However, the prognosis
worsens with advancing stage, and only 5% of patients diagnosed
with distant metastases survive 5 years (Duffy et al, 2003). The
need for biomarkers indicative of cancer status is becoming more
and more evident. Biological markers represent very strong tools
for monitoring the progression of cancer and estimating the
effectiveness and safety of new therapeutic agents (Cho, 2007).
Protein function is often dependent on modifications that occur
on their amino-acid residues. Protein methylation is one such
modification that involves the transport of methyl groups from
S-adenosylmethionine (AdoMet) to target molecules on the protein
substrates. The proteins can be methylated on several residues,
such as arginine residues among others (Aletta et al, 1998). The
methylation of arginine residues on proteins is involved in a
number of different cellular processes, such as regulation of
transcription, RNA metabolism and DNA damage repair (Bedford
and Richard, 2005). The enzymes responsible for this modification
are called protein arginine methyltransferases (PRMTs). The
PRMTs comprise a family of nine protein members so far (Lin
et al, 1996; Scott et al, 1998; Tang et al, 1998; Chen et al, 1999;
Pollack et al, 1999; Frankel et al, 2002; Miranda et al, 2004; Lee
et al, 2005b; Cook et al, 2006) and can be classified into three
distinct classes. Type I enzymes catalyse the formation of
N
G-monomethylarginine and asymmetric N
G,N
G-dimethylargi-
nine residues. Type II enzymes catalyse the formation of
N
G-monomethylarginine and symmetric N
G,N 0G-dimethylarginine
residues. Type III enzymes catalyse monomethylation of the
internal guanidine nitrogen atom to form o-N
G-monomethylargi-
nine (Zobel-Thropp et al, 1998).
The predominant mammalian protein arginine methyltransfer-
ase is PRMT1 (Tang et al, 1998; Frankel et al, 2002). Protein
arginine methyltransferase 1 is a multifunctional protein, im-
plicated in diverse biological processes, such as DNA repair, signal
transduction, protein trafficking and RNA processing (McBride
and Silver, 2001; Boisvert et al, 2003; Bedford and Richard, 2005;
Lee et al, 2005b). Protein arginine methyltransferase 1 methylates a
number of hnRNP molecules, playing a role in the shuttling of
these proteins between the cytoplasm and the nucleus (Herrmann
et al, 2004), and histone H4 at arginine 3 (Wang et al, 2001), a
modification that functions as a transcription activation mark. The
central role that PRMT1 plays as a regulator of protein function is
shown by the disruption of this enzyme in mice. The PRMT1-
knockout mice die shortly after implantation (Pawlak et al, 2000).
Protein arginine methyltransferase 1 prefers to methylate arginine
residues in glycine and arginine rich regions that are often found
in RGG repeats of proteins, such as fibrillarin and nucleolin
(Najbauer et al, 1993; Lee et al, 2005a). The PRMT1 gene is found
on chromosome 19q13.3, in close proximity to the genes RRAS and
IRF3. Genomic organisation, physical mapping and expression
analysis of PRMT1 gene has already been reported by Scorilas et al
(2000).
Primary immunocytochemical localisation studies on RAT1 cells
suggested that PRMT1 is predominantly nuclear (Tang et al, 1998).
In later projects, there has been evidence of the presence of PRMT1
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sin the cytoplasm, suggesting the continuous translocation of the
protein between the nucleus and the cytoplasm (Araya et al, 2005).
Furthermore, according to Herrmann et al, 2005, PRMT1 is a
highly dynamic enzyme with variable subcellular localisation and
mobility.
Methylation processes have been implicated in the emergence
and progression of several diseases, including cancer (Shin et al,
1993; Li et al, 1998; Gu et al, 1999). In this study, the expression of
PRMT1 mRNA was determined, for the first time, by semiquanti-
tative RT–PCR in 120 colon cancer tissues (for 60 of which paired
normal colon mucosa was also examined), 14 adenomas and 24
biopsies of inflamed colon mucosa. The results were associated
with other clinical and pathological parameters. In addition, a
defined number of normal and colon cancer samples were
examined by immunohistochemistry using in-house-produced
polyclonal antibody (anti-PRMT1 IgG) to determine the localisa-
tion of the protein.
MATERIALS AND METHODS
Study group
The tumour specimens of our study were acquired from 120 patients
who underwent surgery for primary colon cancer at the ‘Saint
Savvas’ Oncologic Hospital of Athens. For 60 out of the 120 patients,
paired normal colon mucosa was also examined. Apart from these,
an additional group of 14 adenomas and 24 biopsies of inflamed
colon mucosa were included in the study. Informed consent was
obtained from all patients. The samples were followed by an updated
database containing clinical and histological information about the
tumour (tumour size, grade, stage, etc.) that was used for the
statistical analysis of the results. Patients’ age ranged from 31 to 92
years, with a mean of 67.45±1.08 years. Follow-up information,
which was available for 112 patients, showed that 29 (25.9%) of them
had relapsed and 47 (42%) had died. The staging was performed
according to the TNM staging system, as introduced by the
American Joint Committee on Cancer.
RNA extraction and semiquantitative RT–PCR
Colon tissues were collected on surgery and kept in liquid
nitrogen. The tissue samples were pulverised (Polytron, Kinema-
tica AG, Lucerne, Switzerland) and total RNA was extracted using
TRIzol (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s instructions. Following spectrophotometry deter-
mined the purity and concentration of the RNA. The total RNA
was reverse-transcribed by RT–PCR using the Thermoscript
-RT
(Invitrogen). The integrity of the produced cDNA was examined by
amplification of b-actin gene (housekeeping gene). PCR was
performed in a 20ml reaction mixture containing 0.6ml of cDNA,
2U of Platinum Taq DNA polymerase (Invitrogen), 2mlo f1 0  
PCR buffer (200mM Tris–HCl (pH 8.4), 500mM KCl), 0.8mlo f
50mM MgCl2, 0.4mlo f1 0m M dNTPs mix (Invitrogen) and 0.4mlo f
each gene specific primer (0.1mgml
 1) (Table 1). The amplification
protocol consisted of an initial incubation at 951C for 15min,
followed by 35 cycles of 951C for 30s (denaturing step), 621C for
1min (annealing step), 721C for 1min (extension step) and a final
extension step of 721C for 10min. PCRs were performed on the
PTC-200 thermal cycler (MJ Research Inc., Waltham, MA, USA).
The PRMT1 gene was amplified using a specific set of primers
(Table 1). PCR was performed in a 20ml reaction mixture
containing 0.8ml of cDNA, 2U of Platinum Taq DNA polymerase
(Invitrogen), 2mlo f1 0  PCR buffer (200mM Tris–HCl (pH 8.4),
500mM KCl), 0.8mlo f5 0 m M MgCl2, 0.4mlo f1 0 m M dNTPs mix
(Invitrogen) and 0.4ml of each gene specific primer (0.1mgml
 1).
The amplification protocol consisted of an initial incubation at
951C for 15min, followed by 40 cycles of 951C for 30s (denaturing
step), 64.51C for 1min (annealing step), 721C for 1min (extension
step) and a final extension step of 721C for 10min. PCRs were
performed on the PTC-200 thermal cycler (MJ Research Inc.). The
identity of the products was verified by sequencing, with an
automated DNA sequencer. Equal amounts of PCR products for b-
actin and PRMT1 ran on 1.5% agarose gel, and visualisation was
based on ethidium bromide staining (Figure 1). Densitometric
measurements of band intensities using the Gel Logic 100 Imaging
System and the 1D Image Analysis Software, version 3.6 (Eastman
Kodak Company, Rochester, NY, USA) were used to calculate the
ratio of PRMT1/b-actin. On the basis of this ratio, the expression of
PRMT1 was characterised as high or low, after comparison with
the mean ratio of non-cancer samples. Expression analysis was
performed twice for each sample.
Statistical analysis
The expression of the PRMT1 splice variants was classified as high
or low and was correlated with the clinical and histopathological
features of the patients. The associations between these variables
and PRMT1 status of each variant were analysed using the w
2 test
or the Fisher’s Exact test, where appropriate. Regression analysis
was performed using the Cox proportional hazard regression
model (Cox, 1972) at both univariate and multivariate levels. The
multivariate models were adjusted with TNM stage, patients’ age
and tumour grade. Survival analyses were carried out by
constructing Kaplan–Meier disease-free survival (DFS) curves
and overall survival (OS) curves (Kaplan and Meier, 1958) for all
variants of PRMT1. The differences between the curves were
calculated by the log-rank test.
Production of antibodies
Rabbit polyclonal antibodies against PRMT1 were raised in New
England white rabbits in our lab. The peptide used as an antigen
for the antibody production had the amino-acid sequence
FGTIGMRPNAKNNRDLDFTI and it was synthesised by Invitro-
gen. The produced antibody was purified by affinity chromato-
graphy using A-Sepharose protein beads kindly provided to our
lab by Dr Pigi Lymberi (Department of Biochemistry, Immunology
Lab, Institut Pasteur Hellenique, Athens, Greece).
Immunohistochemistry
Formalin-fixed paraffin-embedded colon tissues from selected
patients expressing PRMT1 were used for the study. Tissue
Table 1 Gene-specific primers used for the amplification of b-actin and
PRMT1 cDNA
Gene Primer sequence Product size (bp)
b-Actin Forward 50-ATCTCGCACCACACCTTCTA-30 372
Reverse 50-CGTCATACTCCTGCTTGCTG-30
PRMT1 Forward 50-GAGGCCGCGAACTGCATCAT-30 283, 331, 385, 502
Reverse 50-TGGCTTTGACGATCTTCACC-30
 v3 
 v2 
 v1 
←
←
←
←
 v4 
1234M5678
1234 M 5678
-Actin
PRMT1
Figure 1 Expression of PRMT1 in normal and cancerous colon tissue.
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ssections (5mm in thickness) were microwave-treated for 15min in
1m M sodium citrate buffer solution (pH¼6.0) for the unmasking
of the antigen, after deparaffinisation and rehydration with xylene
and a series of graded ethanols (100, 90 and 70%). Endogenous
peroxidase activity was blocked with 3% H2O2 for 5min, followed
by 2min washes under flowing normal tap water. The tissue
sections were incubated with 200ml of primary polyclonal antibody
against PRMT1 (anti-PRMT1 IgG), produced in our lab, diluted
1:1500, for 1.5h at room temperature.
Sections were washed for 5min with phosphate-buffered saline
(PBS) solution (pH¼7.4) and incubated for 40min with 200ml
reagent HRP Rabbit/Mouse (ENV) (Dako REALt EnVisiont
Detection System Peroxidase/DABþ, Rabbit/Mouse, Glostrup,
Denmark), containing secondary goat anti-rabbit IgG. Sections
were washed again for 5min with PBS and incubated with 150mlo f
reagent DABþ chromogen (50 ) diluted 1:50 in substrate buffer
(Dako REALt EnVisiont Detection System Peroxidase/DABþ,
Rabbit/Mouse) for 10min. Sections were washed for 5min with
PBS, counterstained for 1min with haematoxylin (Hemacolor,
Merck KGaA, Darmstadt, Germany), dehydrated, cleared and
mounted with DePex (BDH, Limited Poole, Dorset, UK). Negative
controls had the primary antibody omitted and replaced by PBS. Two
pathologists who were unaware of patient history evaluated all samples.
RESULTS
Identification of a new PRMT1 splice variant
The PRMT1 gene was known to give rise to three distinct isoforms
of the same enzyme (Scott et al, 1998; Scorilas et al, 2000), due to
alternative splicing. The sequence of the splice variants that
produce each isoform have been reported by Scorilas et al (2000),
and the variants have been characterised as v1, v2 and v3, v1 being
the shortest one. During the course of this study, the emergence of
an additional gene product came to our attention. After isolation
and sequencing, it appeared to be a new splice variant, 48bp
smaller than v1 that was accessed to GenBank by our lab
(Accession Number AY775289).
PRMT1 status and relation to clinical and
histopathological variables
The expression analysis of PRMT1 in colon cancer patients showed
that only the PRMT1-v1 status and in some cases PRMT1-v2 status
effectively associate with clinical or histological parameters, of all
four variants expressed in colon tissue, due to alternative splicing.
Table 2 shows the distribution of numerical variables in the
study group. Table 3 presents the expression pattern of variant
PRMT1-v1 in the different colon tissues. We have used as a cutoff
value the mean of the background values þ2 s.d. P-value was
calculated using w
2 test and shows that high expression of PRMT1-
v1 is associated with statistical significant probability to the type of
tissue (Po0.001). The statistical analysis of the PRMT1-v1 status in
relation to nodal status, TNM stage and tumour grade was
performed using the parametric Fisher’s Exact test and the w
2 test
(Table 4). High expression of PRMT1-v1 seems to associate in a
statistically significant manner with highly malignant tumours
(P¼0.005), tumours of advanced TNM stage (P¼0.001) and
tumours with positive nodal status with a low statistical power
(P¼0.042). Statistically significant relationships between tumour
size and PRMT1 expression levels was not observed while using the
Mann–Whitney non-parametric test.
Survival analysis
The associations between PRMT1 gene expression and DFS as well
as OS, in both univariate and multivariate analysis, are presented
on Table 5. According to Cox univariate analysis, high expression
of PRMT1-v1 is significantly associated with the OS (HR¼2.24,
P¼0.008) and, to a smaller extent, with DFS (HR¼3.81,
P¼0.011), whereas high expression of PRMT1-v2 seems to
associate only with OS (HR¼2.41, P¼0.026). On the other hand,
multivariate analysis shows no significant relationship between
PRMT1 expression and DFS or OS. Survival curves created
according to the Kaplan–Meier method for DFS and OS showed
that low expression of PRMT1-v1 relates to longer DFS and OS
(P¼0.004 and P¼0.006, respectively) (Figure 2). Additionally, low
expression of PRMT1-v2 seems to associate with longer DFS and
OS in a similar manner (P¼0.024 and P¼0.021, respectively)
(Figure 3).
Localisation of the PRMT1 protein
Selected cancer and normal colon samples were stained for PRMT1
(Figure 4). The primary antibody against PRMT1 was raised in our
lab and its binding ability to the substrate was checked on western
Table 2 Distribution of numerical values
Variable Mean+s.e. Range
Percentiles
10 25 50 75 90
(Median)
Age (years) 67.5±1.1 31–92 51.6 60.0 70.0 76.0 81.0
Tumour size (cm) 4.48±0.17 1.80–12.0 2.57 3.50 4.20 5.05 6.50
DFS (months) 37.3±2.8 0.0–132.0 0.0 0.0 48.0 58.0 64.0
OS (months) 46.7±2.4 1.0–132.0 12.0 26.0 48.0 58.7 65.0
Table 3 Expression status of PRMT1 variant v1 in colon tissues
Tissue
No. of patients (%)
Total
PRMT1-v1
status low
a
PRMT1-v1
status high
a P-value
b
Non-cancer 83 72 (86.7) 11 (13.3)
Adenomas 14 11 (78.6) 3 (21.4) o0.001
Cancer 120 63 (52.5) 57 (47.5)
aPRMT1/b-actin.
bw
2 test. Statistically significant values are in bold.
Table 4 Associations between status of PRMT1 variant v1 and other
variables in colon cancer patients
No. of patients (%)
Variable Total
PRMT1-v1
status low
a
PRMT1-v1
status high
a P-value
Nodal status
Negative 40 27 (67.5) 13 (32.5) 0.042
b
Positive 61 28 (45.9) 33 (54.1)
TNM stage
I 44 31 (70.5) 13 (29.5) 0.001
b
II–III 44 15 (34.1) 29 (65.9)
Grade
I 9 6 (66.7) 3 (33.3)
II 36 26 (72.2) 10 (27.8) 0.005
c
III 46 17 (37.0) 29 (63.0)
aPRMT1/b-actin.
bFisher’s exact test.
cw
2 test. Statistically significant values are in bold.
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sblotting. In both normal and cancer colon tissues staining is very
intense on the cytoplasm and only in rare cases the cell nucleus
appeared stained.
DISCUSSION
Protein arginine methylation is a major post-translational
modification that seems to regulate a variety of cellular processes,
such as signal transduction, RNA metabolism, chromatin struc-
ture, RNA and protein trafficking. The enzymes responsible for
this type of modification are the PRMTs. Protein arginine
methyltransferase 1 represents the prevalent protein methyltrans-
ferase in human cells. The major targets of PRMT1 include
components of the hnRNPs (Nichols et al, 2000), histone H4
(Wang et al, 2001) and peroxisome proliferator-activated receptor
g coactivator 1a (Teyssier et al, 2005).
It is known for a long time now that alterations in the expression
pattern of certain genes are strongly correlated with cancer incidence.
Most of these genes are involved in developmental processes and cell
cycle-regulatory events, such as MLH1 and MLH2, TP53, LKB1,a sf a r
as colon cancer is concerned. Although the physiological role of
PRMT1 is not fully elucidated yet, several hypotheses have been
made. Among others, a role in cancer has been suggested for this
enzyme. In this study, the possible role of PRMT1 as a new biomarker
for colon cancer was examined. The tissue samples used for the study
were not selected for proximal or distal splenic flexure, as, so far,
evidence as to the existence of two sides in colorectal cancer from
different studies are still quite contradictory (Iacopetta, 2002).
Statistical analysis of the results, concerning semiquantitative
measurements of PRMT1 expression, showed association between
the expression of PRMT1-v1 splice variant and clinical and
histological data of the tumours. First of all, the expression of v1
variant seems to increase following the progression from normal
tissue to adenoma and finally cancer. The levels of v1 isoform are
Table 5 Associations of PRMT1 variants v1 and v2 expression with DFS
and OS
Disease-free survival Overall survival
Variable HR
a 95% CI
b P-value HR
a 95% CI
b P-value
Univariate analysis
PRMT1-v1
Negative 1.00 1.00
Positive 3.81 1.35–10.73 0.011 2.24 1.23–4.09 0.008
PRMT1-v2
Negative 1.00 1.00
Positive 1.66 0.38–7.32 0.49 2.41 1.11–5.22 0.026
Multivariate analysis
c
PRMT1-v1
Negative 1.00 1.00
Positive 1.69 0.54–5.32 0.37 0.84 0.366–1.94 0.69
PRMT1-v2
Negative 1.00 1.00
Positive 0.38 0.041–3.61 0.41 0.98 0.35–2.71 0.97
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConfidence interval of the estimated HR.
cThe multivariate models were adjusted
with TNM stage, patient age and tumour grade. Statistically significant values are in
bold.
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Figure 2 Prognostic value of PRMT1-v1 expression in colon cancer
patients (P-value was calculated by the log-rank test. The small vertical lines
indicate the censoreds. Censored cases refer to the number of patients that
have not reached the terminal event during our study).
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Figure 3 Prognostic value of PRMT1-v2 expression in colon cancer
patients (P-value was calculated by the log-rank test. The small vertical lines
indicate the censoreds. Censored cases refer to the number of patients that
have not reached the terminal event during our study).
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ssignificantly higher in colon cancer tissue compared with normal
tissue. In accordance with the above findings, high expression of
PRMT1-v1 seems to be indicative of the disease progression and
aggressiveness. It seems that the higher the malignancy grade, the
greater the expression of the variant. Additionally, both advanced
TNM stage and presence of positive lymph nodes are linked in a
statistically significant manner to high v1 variant expression.
Survival analysis was performed with both Cox proportional
hazard regression model and Kaplan–Meier method. The uni-
variate Cox analysis showed a profound relation of high PRMT1-v1
expression and both DFS and OS of patients. Patients expressing
strongly the v1 variant show higher probability to relapse or die,
compared with patients with low expression. In line with
univariate Cox regression analysis, Kaplan–Meier survival plots
also indicate a low survival probability for the individuals that
express highly the v1 variant.
As far as the other three isoforms are concerned, the association
between their expression patterns and other parameters is not very
strong. In the case of v2, survival analysis gives low survival
probabilities and higher chance of relapse for patients highly expressing
the v2 variant. But these associations are much weaker than those
regarding the expression of PRMT1-v1. Similarly, the presence of
PRMT1-v1 seems to be associated with clinical and pathological features
and poor prognosis in breast cancer patients (our unpublished data).
Approximately, 10–30% of alternatively spliced human genes
have tissue-specific variants (Xu et al, 2002), whereas 316 genes
have been shown to have cancer-specific variants (Xu and Lee,
2003). Production of alternative transcripts may be a consequence
of disease such as cancer (Mercatante and Kole, 2000). These
findings seem to be in accordance with the presence of PRMT1-v4
splice variant in colon tissue (normal and cancerous) but not in
breast tissue (our unpublished data).
The product of PRMT1 gene is still under intense study. There
are many things to be defined and clarified. One of them is the
behaviour of the protein in the cell. There is conflicting evidence
about the localisation site of the protein (Tang et al, 1998; Araya
et al, 2005). It is known that in different cell lines the proteins in
need of methylation can vary both in quantity and quality. As a
result, methyltransferases are expected to function either in the
nucleus or the cytoplasm, depending on the localisation of their
substrates. Results from the immunohistochemical experiments
performed in our lab, in normal and cancer colon tissues,
indicated that the protein resides mainly in the cytoplasm. Its
presence in the nucleus is rare. The same pattern was noticed in
breast tissue, which is also epithelial (our unpublished data). It is
quite strange for an enzyme that methylates arginine residues
mostly on nuclear proteins to be found to such an extent in the
cytoplasm. This could probably be attributed to the fact that
methylation occurs during or shortly after translation, so the
enzyme needs to reside in the cytoplasm. The mechanism used by
the protein to exit the nucleus at one time and still be able to
return is yet unknown. Experiments by Herrmann et al (2005)
indicate that PRMT1 has the ability to move between nucleus and
cytoplasm, probably piggybacked on unmethylated substrates that
carry them through the nuclear pore (Herrmann et al, 2005).
Data from this study suggest that PRMT1 gene variant v1
expression may be used as a marker of unfavourable prognosis for
colon cancer patients. Studies on the physiological function of
PRMT1 in normal colon will shed more light into the role of this
enzyme in cancer as well as other diseases. The PRMT1 gene
combined with other markers could be proven useful for physicians.
Nevertheless, more extensive study is needed to establish a role for
PRMT1 as a potential biological prognostic marker.
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Figure 4 Immunohistochemical localisation of PRMT1 protein in colon tissue. (A) Normal colon, negative control (primary antibody omitted) ( 100),
(B) normal colon tissue ( 125), (C) cancerous colon tissue ( 150) and (D) cancerous colon tissue ( 100).
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